- Home
- SLXN vs MGRX Comparison
SLXN vs MGRX Comparison
Compare SLXN & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- MGRX
- Stock Information
- Founded
- SLXN 2008
- MGRX 2021
- Country
- SLXN Israel
- MGRX United States
- Employees
- SLXN N/A
- MGRX N/A
- Industry
- SLXN
- MGRX Computer Software: Prepackaged Software
- Sector
- SLXN
- MGRX Technology
- Exchange
- SLXN NYSE
- MGRX Nasdaq
- Market Cap
- SLXN 6.9M
- MGRX 8.1M
- IPO Year
- SLXN N/A
- MGRX 2023
- Fundamental
- Price
- SLXN $0.95
- MGRX $2.04
- Analyst Decision
- SLXN Strong Buy
- MGRX
- Analyst Count
- SLXN 1
- MGRX 0
- Target Price
- SLXN $5.00
- MGRX N/A
- AVG Volume (30 Days)
- SLXN 1.2M
- MGRX 202.3K
- Earning Date
- SLXN 05-13-2025
- MGRX 05-15-2025
- Dividend Yield
- SLXN N/A
- MGRX N/A
- EPS Growth
- SLXN N/A
- MGRX N/A
- EPS
- SLXN N/A
- MGRX N/A
- Revenue
- SLXN N/A
- MGRX $511,084.00
- Revenue This Year
- SLXN N/A
- MGRX N/A
- Revenue Next Year
- SLXN N/A
- MGRX N/A
- P/E Ratio
- SLXN N/A
- MGRX N/A
- Revenue Growth
- SLXN N/A
- MGRX N/A
- 52 Week Low
- SLXN $0.58
- MGRX $1.32
- 52 Week High
- SLXN $41.85
- MGRX $7.66
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- MGRX 52.44
- Support Level
- SLXN N/A
- MGRX $2.05
- Resistance Level
- SLXN N/A
- MGRX $2.28
- Average True Range (ATR)
- SLXN 0.00
- MGRX 0.24
- MACD
- SLXN 0.00
- MGRX 0.06
- Stochastic Oscillator
- SLXN 0.00
- MGRX 57.56
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.